Velsera
Velsera is a global precision medicine technology company that accelerates the discovery, development, and delivery of precision medicine through integrated AI-enhanced software and expert services. The company offers a suite of cutting-edge platforms including the Seven Bridges Trusted Research Environment for bioinformatic analysis, the award-winning GRAF reference genome tool, the ARIA data harmonization and secure sharing platform, the Clinical Genomics Workspace for tertiary analysis and reporting, and an IVD-grade variant interpretation Knowledgebase. Velsera serves biotech and pharmaceutical companies, clinical diagnostic labs, NGS assay and equipment manufacturers, and non-profits and government agencies, helping them unlock and harmonize clinical and multi-omic data to accelerate research breakthroughs and scale genetic testing. With over 80 active clinical NGS lab customers, more than 250,000 NGS samples sequenced, and 18,000 researchers using its platforms, Velsera is positioned as one of the largest omics analytics providers, supporting top pharmaceutical companies and advancing precision medicine globally.
Velsera
Velsera is a global precision medicine technology company that accelerates the discovery, development, and delivery of precision medicine through integrated AI-enhanced software and expert services. The company offers a suite of cutting-edge platforms including the Seven Bridges Trusted Research Environment for bioinformatic analysis, the award-winning GRAF reference genome tool, the ARIA data harmonization and secure sharing platform, the Clinical Genomics Workspace for tertiary analysis and reporting, and an IVD-grade variant interpretation Knowledgebase. Velsera serves biotech and pharmaceutical companies, clinical diagnostic labs, NGS assay and equipment manufacturers, and non-profits and government agencies, helping them unlock and harmonize clinical and multi-omic data to accelerate research breakthroughs and scale genetic testing. With over 80 active clinical NGS lab customers, more than 250,000 NGS samples sequenced, and 18,000 researchers using its platforms, Velsera is positioned as one of the largest omics analytics providers, supporting top pharmaceutical companies and advancing precision medicine globally.